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Summary 
• The Bill will curb, but not extinguish, the tobacco industry’s opportunities for 
policy influence. 
• Modest, but vitally important, changes to the Bill can increase compliance with 
Article 5.3 of the World Health Organization (WHO) Framework Convention 
on Tobacco Control (FCTC) significantly, protecting tobacco control policy from 
industry interference. 
• Clause 8(1) of the Bill does not restrict the tobacco industry’s ability to use third 
parties – such as business associations – to lobby on its behalf. Further, the Bill’s 
restrictions on lobbying do not extend to MPs and will not extend to all public 
bodies. Extending the scope of clause 8(1) in line with the Guidelines for 
Implementation will strengthen the protection of health policy from tobacco 
industry interference. 
• Clause 7(2) seeks to make interactions which occur between public officials and 
the industry transparent to the public. However, there is a risk that this provision 
will be interpreted narrowly, and interactions will not be made fully public in line 
with best practice.  
• Clauses 9(3), 10(1) and (2) strengthens the law relating to individual conflicts of 
interest among public officials and the tobacco industry. However, they do not 
extend to MPs, which creates opportunities for continuing industry political 
influence. 
• The “disclosure clauses” in the Bill (clauses 25 and 26) do not require the tobacco 
industry and any organisation working to further its interests to periodically 
submit information on lobbying and other forms of political activity. Amending 
the “disclosure clauses” to include tobacco industry political activity will reduce 
the costs of industry monitoring significantly and further strengthen health policy   
from tobacco industry interference.
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1. Introduction 
In this submission, we discuss the Tobacco Control Bill’s provisions covering tobacco industry 
interference in health policy. We begin by describing the importance of comprehensive 
implementation of the Guidelines for Implementation of Article 5.3 of the World Health 
Organization (WHO) Framework Convention on Tobacco Control (FCTC), which seek to 
prevent tobacco industry interference in health policy making. We then go on to discuss the 
strengths and weakness of the Bill in implementing the Guidelines based on research conducted 
with the Jamaica Coalition for Tobacco Control.1 Finally, we present recommendations on how 
the Bill can be strengthened to ensure strong implementation of the Guidelines. 
2. Tobacco Industry Interference in Health Policy and the Guidelines for 
Implementation of Article 5.3 of the WHO FCTC 
Jamaica ratified the WHO FCTC in July 2005. Article 5.3 of the Treaty requires parties to 
insulate the development of public health policies from tobacco industry political influence. The 
Article is the first of its kind in an international treaty and reflects the decisive role major 
tobacco companies have played, and continue to play, in disrupting and weakening tobacco 
control policies and their implementation.  
Tobacco industry political influence is widely recognized as a key cause of weak implementation 
of tobacco control policy internationally.2-11 Guidelines for Implementation of Article 5.3 
published in 200812 contain 34 specific recommendations outlining how parties should meet 
their obligations under the Article. These focus on enhancing governments’ capacity to monitor 
the industry’s political activities, curbing insider political strategies, managing and eliminating 
conflicts of interest within health policy-making, and prohibiting financial and other forms of 
support to the industry. 
As one of several similar documents adopted at sessions of the Conference of the Parties, the 
governing body of the FCTC, the guidelines constitute a subsequent agreement under Article 
31 of the Vienna Convention on the Law of Treaties 1969 and, therefore, should be taken into 
account by parties in interpreting their obligations under Article 5.3.  
Five common weaknesses in implementing the Guidelines Recommendations  
Implementation of the Guidelines in many countries is selective and incomplete.2 Measures 
aimed at preventing industry interference commonly have the following flaws: 
• fail to cover all policy actors (including senior policy actors); 
• fail to cover all parts of public administration; 
• fail to include third parties in prohibitions and restrictions on tobacco industry political 
activity; 
• fail to place the responsibility on tobacco companies to disclose their political activities; 
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• fail to address efforts by the tobacco industry to strength their structural advantages in 
policy-making (through, for example, trade and investment agreements).2 
Five risks of weak implementation of the Guidelines Recommendations  
Gaps in implementation of the Guidelines have potentially far-reaching implications for 
continuing industry influence in health policy-making. This is because tobacco industry political 
activity is varied, mutable, and capable of adapting to changing political and institutional 
conditions, including selective and incomplete implementation of the Guidelines.13,14 Five 
characteristics of this political plasticity are relevant to understanding the industry’s ongoing 
capacity for political interference. 
• Tobacco companies seek out alternative venues to supersede or circumvent health 
ministries, which is typically the lead department on FCTC implementation and a “veto 
point” for tobacco industry political activity.15,16 This political venue-shopping is carried out 
to exploit different priorities of decision-makers in different parts of government.2,17-19 
• Tobacco companies often substitute one technique for another. This is illustrated by their 
use of corporate social responsibility (CSR) activities to gain informal access to difficult-to-
reach public officials.18,20-22 
• Industry actors draw on the support of third parties. This is done either to leverage the 
greater credibility of third parties or when industry actors are excluded from policy-making 
processes or are otherwise refused access to policy actors.13,14,23,24 
• Industry actors shift the policy focus of existing techniques. One example of this is strategic 
partnerships. These are now increasingly advocated by major tobacco companies in relation 
to the illicit trade in tobacco in order to facilitate political access and embed themselves in 
policy-making networks relevant to tobacco taxation.3,13,25 
• Tobacco companies’ efforts to shape trade and investment agreements26,27 and embed cost-
benefit analysis and risk assessment into policy decision-making28,29 illustrate their success 
in establishing new forms, or levels, of political governance. These strengthen their 
institutional advantage within health policy-making.27-29 
Minimising policy risks and comprehensive implementation of the Guideline Recommendations 
The above characteristics of industry influence underline the importance of comprehensive 
implementation of Article 5.3 and its guidelines. Selective or incomplete implementation of 
specific guideline recommendations simply preserves opportunities for industry influence. These 
opportunities have a cumulative and mutually reinforcing effect on the industry’s ability to build 
consensus within government and legislatures against policy change and implementation.2 
3. The Strengths of the Tobacco Control Bill in implementing Article 5.3 
Present Implementation of Article 5.3 
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Historically, government efforts to implement Article 5.3 have been poor. Our research 
suggests that formal compliance with the Guidelines is currently 4.8 on a scale of 0-26 or just 
18%. 
Key Guideline Recommendations have not yet been acted on. Presently, the Government has 
failed to act on several key Guideline Recommendations which are critical to effective health 
policy in Jamaica. These include those aimed at: direct lobbying; restricting the “revolving door” 
between politics and the tobacco industry; banning tobacco industry “corporate social 
responsibility” outright; requiring tobacco companies to disclose evidence of their efforts to 
influence Jamaican politics. 
Article 5.3 and the Tobacco Control Bill 
The Tobacco Control Bill represents a major improvement on Article 5.3 implementation. Our 
research suggests that it will increase the government's compliance to 18 or 69%.1 However, 
the Bill will curb, but not extinguish, the tobacco industry’s opportunities for policy influence. 
The Bill is particularly strong in relation to tobacco industry CSR (Recommendations 6.2-6.4 of 
the Guidelines) and some institutional conflicts of interest such as political funding 
(Recommendation 4.11) and government subsidies (Recommendations 7.1-7.3). CSR is widely 
understood to be a political tactic used to gain access to policy elites, build political 
constituencies, and tie tobacco companies, misleadingly, in the public imagination to social and 
economic development.18,20-22,30,31 The Bill's restrictions on tobacco industry sponsorship will 
effectively prohibit tobacco companies from using CSR to influence policy, as well as banning 
contributions to political parties, elected representatives and candidates for public office. 
Equally, clause 9(3)(a) of the Bill covers tax exemptions and other benefits to tobacco companies 
(also see here for a brief discussion of the implications of clause 9(3)(b) for tobacco industry 
divestment). 
Further, Recommendations 3.1, 3.2 and 3.3 of the Guidelines urge governments to avoid 
partnerships, non-binding agreements, and voluntary arrangements with the tobacco industry 
as well as advocating that they refrain from becoming involved with or endorsing tobacco 
industry youth and public education initiatives and voluntary codes. Recommendation 3.4 urges 
governments to refrain from accepting assistance from the tobacco industry in developing 
tobacco control policies. Clause 9(1) of the Bill will effectively implement these 
recommendations in full. Given the threat that partnerships and offers of assistance in policy 
development pose to strong public health policies going forward, it is vital that this clause is 
passed into law in its entirety. 
4. The Weaknesses of the Tobacco Control Bill in implementing Article 
5.3 
Restrictions on Government-Industry Interactions 
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Recommendation 2.1 of the Guidelines encourages parties to limit the effectiveness of tobacco 
industry lobbying by restricting interactions with the industry only when and to the extent 
strictly necessary to enable them to effectively regulate the tobacco industry and tobacco 
products. This is addressed by clause 8(1) of the Bill, which states that “a person who acts on 
behalf of or for the benefit of a public body which has responsibility for tobacco control" shall 
not interact with a "person in the tobacco industry in furtherance of a business activity, except 
where it is strictly necessary so to do.” 
In the modern era, the industry lobbies officials across government departments (including 
customs and excise, trade, and finance departments) to influence the taxation of tobacco 
products and trade and investment agreements.2,24,27 It also uses third parties - such as general 
business associations - to lobby on its behalf.2,24 
The Bill does not cover these key forms of lobbying. This is partly because of how the "tobacco 
industry" is defined in clause 2 of the Bill - i.e. "tobacco manufacturers, wholesale distributors, 
importers, and exporters of tobacco products." This definition does not cover third parties. 
Further, only officials acting "on behalf of" or working for "the benefit of" a "public body which 
has responsibility for tobacco control" are subject to the restrictions. This may potentially 
exclude persons working outside of health-related departments, with whom the tobacco 
industry is keen to engage (see, for example, here).  
Transparency of Government-Industry Interactions 
Clause 7(2) of the Bill seeks to make interactions which occur between public officials and the 
industry transparent to the public in line with Recommendation 2.2 of the Guidelines. This is 
necessary to ensure that the Jamaican public can call out the industry when it seeks to influence 
health policy. The clause also states that “the Minister shall ensure that all records and 
documents relating to the interactions and communications between the Government and the 
tobacco industry be made available to the public.” 
There is a risk that this provision will be interpreted narrowly, partly because of how the 
tobacco industry is defined in the bill, partly because it does not explicitly extend to all parts of 
government, and partly because the passage in 8(2) which notes that interactions should be 
"documented" does not spell out that they should be recorded and minuted. Other countries 
have introduced protocols, which ensure that all interactions are recorded and minuted and, 
importantly, that minutes of interactions are made publicly available for inspection.32 
Conflicts of Interest and Parliamentary Representatives 
MPs are not included in the Tobacco Control Bill's provisions, which aim to manage conflicts of 
interest in public administration. 
Clause 9(3)(b) of the Bill provides that a person "employed with a public body" shall not "invest 
in the tobacco industry or any related ventures". Further, clause 10(1) of the Bill notes that a 
6  
person "employed with a public body" shall not "engage in any occupational activity, which may 
create a conflict of interest". Neither provision covers MPs because of how "public bodies" are 
defined in the Bill - i.e. as "a ministry or department of Government, including a statutory body 
or authority, a government company, and an agency designated as an executive agency under 
the Executive Agencies Act." 
Tobacco Industry Transparency and Industry Monitoring 
Recommendations 5.2 and 5.3 of the Guidelines urge governments to require the tobacco 
industry and any organisation working to further its interests to periodically submit information 
on lobbying and other forms of political activity and for a register of tobacco industry lobbyists 
(broadly defined) to be created. These recommendations are central to facilitating cost-effective 
monitoring of the tobacco industry’s political activities. Clauses 25 and 26 of the Bill - which 
cover the industry’s disclosure requirements – fail to cover the industry’s political activities. 
5. Recommendations to protect Health Policy from the Tobacco 
Industry Interference 
Our research suggests that modest, but vitally important, changes to the Bill can increase 
compliance significantly to 20 or 77%. 
Restrictions on Government-Industry Interactions 
Strong implementation of Article 5.3 would require minor amendments to clause 8(1) so that 
it includes persons acting on behalf of the tobacco industry and all public officials. This could be 
achieved as follows:  
“a person who acts on behalf of or for the benefit of a public body, the activities of 
which have an effect on tobacco control, shall not, whether in the person’s individual 
capacity or otherwise interact in any manner whatsoever, with a person in the tobacco 
industry or any entity working to further its interests in furtherance of a business 
activity, except where it is strictly necessary so to do, in order to ensure the effective 
regulation of the tobacco industry, a tobacco product or relevant product.”1 
Transparency of Government-Industry Interactions 
To ensure implementation of Article 5.3 at best-practice level the Bill should, ideally, include a 
provision empowering the Minister to introduce a Protocol governing interactions between 
representatives of the tobacco industry and public officials and how they are made transparent. 
Ideally, the protocol should apply to all public officials, including government ministers, MPs and 
 
1 We note for the sake of completeness that the proposed form of words would not include interactions with 
MPs. 
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their staff and civil servants. Similar protocols introduced elsewhere32 limit all interactions 
(meetings, telephone conversations, correspondence) between tobacco industry 
representatives (which includes those working to further the interests of the industry) and all 
public officials to technical matters relating to the implementation of tobacco control policy. 
Further, in line with best-practice the protocol should: 
• limit meetings (including digital meetings and conference calls) to industry actors named in 
advanced in writing; 
• require a pre-determined agenda for all meetings (including digital meetings and conference 
calls); 
• stipulate that interactions are recorded and minuted (and that minutes include the method 
of interaction, the names of the parties and individuals involved, the matters discussed, and 
decisions taken, and any follow up activity planned or anticipated); 
• ensure that meetings take place on official premises and that a lawyer is present; 
• mandate that the public is given full and free access to all relevant information regarding 
interactions, including dates, those in attendance, and minutes; 
• prohibit all side meetings, hospitality or meetings at social events. 
An alternative would be to amend clause 8(2) to specify that all interactions shall be 
"transparent and recorded and minuted" and for clause 7(2) to be amended to ensure that 
interactions across public bodies are made fully transparent: 
“Pursuant to subsection 1(c) the Minister shall ensure that all records and 
documents relating to interactions and communications between public bodies and 
the tobacco industry and those working to further its interests are made freely 
accessible to the public.” 
Conflicts of Interest and Parliamentary Representatives 
Implementation of Article 5.3 at best-practice level would require amendment of all individual 
conflict of interest provisions in the Bill so that they include persons "employed with a public 
body and elected representatives". Alongside this a definition of "elected representatives" 
would need to be included in the interpretative provisions of the Bill (clause 2), which covers 
all MPs and local government elected representatives. 
Transparency in Health Policy-Making and Effective Monitoring 
Amending clauses 25 and 26 of the Bill - which cover the industry's disclosure requirements –
so that they extended to the tobacco companies' political activities would represent a highly 
effective, cost efficient means of strengthening the ability of public officials, civil society, and the 





1. Fooks G, McGaw B. Controlling Tobacco Industry Interference in Tobacco Control Policy in Jamaica. Birmingham: Aston 
University and Jamaica Coalition for Tobacco Control;2020. 
2. Fooks GJ, Smith J, Lee K, Holden C. Controlling corporate influence in health policy making? An assessment of 
the implementation of article 5.3 of the World Health Organization framework convention on tobacco control. 
Globalization and Health. 2017;13(1):12. 
3. Gilmore AB, Fooks G, Drope J, Bialous SA, Jackson RR. Exposing and addressing tobacco industry conduct in 
low-income and middle-income countries. The Lancet. 2015;385(9972):1029-1043. 
4. Chung-Hall J, Craig L, Gravely S, Sansone N, Fong GT. Impact of the WHO FCTC over the first decade: a global 
evidence review prepared for the Impact Assessment Expert Group. Tobacco control. 2019;28(Suppl 2):s119-s128. 
5. Gravely S, Giovino GA, Craig L, et al. Implementation of key demand-reduction measures of the WHO 
Framework Convention on Tobacco Control and change in smoking prevalence in 126 countries: an association 
study. The Lancet Public Health. 2017;2(4):e166-e174. 
6. Crosbie E, Sosa P, Glantz SA. The importance of continued engagement during the implementation phase of 
tobacco control policies in a middle-income country: the case of Costa Rica. Tobacco Control. 2017;26(1):60-68. 
7. Hiilamo H, Glantz S. FCTC followed by accelerated implementation of tobacco advertising bans. Tobacco Control. 
2017;26(4):428-433. 
8. Wisdom JP, Juma P, Mwagomba B, et al. Influence of the WHO framework convention on tobacco control on 
tobacco legislation and policies in sub-Saharan Africa. BMC Public Health. 2018;18(1):954. 
9. Egbe CO, Bialous SA, Glantz S. Framework Convention on Tobacco Control Implementation in Nigeria: Lessons 
for Low- and Middle-Income Countries. Nicotine & Tobacco Research. 2018;21(8):1122-1130. 
10. Egbe CO, Bialous SA, Glantz SA. Avoiding “A Massive Spin-Off Effect in West Africa and Beyond”: The Tobacco 
Industry Stymies Tobacco Control in Nigeria. Nicotine & Tobacco Research. 2017;19(7):877-887. 
11. Assunta M, Dorotheo EU. SEATCA Tobacco Industry Interference Index: a tool for measuring implementation 
of WHO Framework Convention on Tobacco Control Article 5.3. Tobacco control. 2016;25(3):313-318. 
12. World Health Organization. Guidelines for Implementation of Article 5.3 of the WHO Framework Convention on 
Tobacco Control on the Protection of Public Health Policies With Respect to Tobacco Control From Commercial and Other 
Vested Interests of the Tobacco Industry. Geneva: World Health Organization;2008. 
13. Ulucanlar S, Fooks GJ, Gilmore AB. The Policy Dystopia Model: An Interpretive Analysis of Tobacco Industry 
Political Activity. PLOS Medicine. 2016;13(9):e1002125. 
14. Savell E, Gilmore AB, Fooks G. How Does the Tobacco Industry Attempt to Influence Marketing Regulations? A 
Systematic Review. PLoS ONE. 2014;9(2):e87389. 
15. Martin E, de Leeuw E. Exploring the implementation of the framework convention on tobacco control in four 
small island developing states of the Pacific: a qualitative study. BMJ Open. 2013;3(12). 
16. Tsebelis G. Veto Players:How Political Institutions Work. Princeton, NJ: Princeton University Press; 2002. 
17. Gruning T, Weishaar H, Collin J, Gilmore AB. Tobacco industry attempts to influence and use the German 
government to undermine the WHO Framework Convention on Tobacco Control. Tob Control. 2012;21(1):30-38. 
18. Fooks GJ, Gilmore AB, Smith KE, Collin J, Holden C, Lee K. Corporate Social Responsibility and Access to Policy 
Élites: An Analysis of Tobacco Industry Documents. PLoS Med. 2011;8(8):e1001076. 
9  
19. Balwicki Ł, Stokłosa M, Balwicka-Szczyrba M, Tomczak W. Tobacco industry interference with tobacco control 
policies in Poland: legal aspects and industry practices. Tobacco Control. 2016;25(5):521-526. 
20. Tesler LE, Malone RE. Corporate philanthropy, lobbying, and public health policy. American journal of public health. 
2008;98(12):2123-2133. 
21. McDaniel PA, Malone RE. Creating the "desired mindset": Philip Morris's efforts to improve its corporate image 
among women. Women Health. 2009;49(5):441-474. 
22. Fooks G, Gilmore A, Collin J, Holden C, Lee K. The Limits of Corporate Social Responsibility: Techniques of 
Neutralization, Stakeholder Management and Political CSR. J Bus Ethics. 2013;112(2):283-299. 
23. Apollonio DE, Bero LA. The Creation of Industry Front Groups: The Tobacco Industry and “Get Government 
Off Our Back”. American Journal of Public Health. 2007;97(3):419-427. 
24. Hatchard JL, Fooks GJ, Gilmore AB. Standardised tobacco packaging: a health policy case study of corporate 
conflict expansion and adaptation. BMJ Open. 2016;6(10):e012634. 
25. Crosbie E, Bialous S, Glantz SA. Memoranda of understanding: a tobacco industry strategy to undermine illicit 
tobacco trade policies. Tobacco Control. 2019;28(e2):e110-e118. 
26. Mamadu HM. The interlocking world of global health governance: the tobacco industry, bilateral investment 
treaties and health policy. In: Freeman M, Hawkes S, Bennett B, eds. Law and Global Health. Oxford: Oxford University 
Press; 2014. 
27. Fooks G, Gilmore AB. International trade law, plain packaging and tobacco industry political activity: the Trans-
Pacific Partnership. Tobacco Control. 2013;23. 
28. Smith KE, Fooks G, Collin J, Weishaar H, Mandal S, Gilmore AB. "Working the system"--British American 
tobacco's influence on the European union treaty and its implications for policy: an analysis of internal tobacco 
industry documents. PLoS Med. 2010;7(1):1000202. 
29. Smith KE, Fooks G, Gilmore AB, Collin J, Weishaar H. Corporate Coalitions and Policy Making in the European 
Union: How and Why British American Tobacco Promoted "Better Regulation". Journal of health politics, policy and 
law. 2015;2:2882231. 
30. Fooks GJ, Gilmore AB. Corporate Philanthropy, Political Influence, and Health Policy. PLoS One. 
2013;8(11):e80864. 
31. Tesler LE, Malone RE. Corporate philanthropy, lobbying, and public health policy. Am J Public Health. 
2008;98(12):2123-2133. 
32. Health AGDo. Guidance for Public Officials on Interacting with the Tobacco Industry. Canberra: Department of 
Health;2019. 
 
